BAGSVAERD, Denmark, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Sales increased by 8% in local currencies and by 4% in Danish kroner to DKK 64.2 billion during the first nine months of 2014 compared to the same period in 2013.
- Sales of modern insulin increased by 13% (8% in Danish kroner).
- Sales of Victoza® increased by 15% (12% in Danish kroner).
- Sales in North America increased by 11% (7% in Danish kroner).
- Sales in International Operations increased by 13% (1% in Danish kroner).
- Sales in Region China increased by 14% (11% in Danish kroner).
Gross margin improved by 1.0 percentage point in Danish kroner to 83.6% driven by a favourable price development as well as a positive impact from product mix and productivity.
Operating profit increased by 11% in local currencies and by 5% in Danish kroner to DKK 25.3 billion.
Net profit increased by 4% to DKK 20.0 billion. Diluted earnings per share increased by 7% to DKK 7.56.
The roll-out of Tresiba® continues. In Japan, Tresiba® now represents 24% of the basal insulin market measured in monthly value market share.
In September, the European Commission granted marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults. Xultophy® is a fixed combination of insulin degludec (Tresiba®) and liraglutide (Victoza®).
For 2014, sales growth measured in local currencies is now expected to be 7-9% and operating profit growth measured in local currencies is still expected at around 10%.
The preliminary outlook for 2015 indicates high single-digit sales growth and around 10% operating profit growth, both measured in local currencies.
Lars Rebien Sørensen, CEO: "We are satisfied with the financial results for the first nine months of 2014. In the US, Levemir® continues to perform well, and with the approval of Xultophy® in Europe we now look forward to launching this product in the first half of 2015."
Contacts for further information
|Mike Rulis||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 514 firstname.lastname@example.org|
|Kasper Roseeuw Poulsen||+45 3079 email@example.com|
|Jannick Lindegaard Denholt||+45 3079 firstname.lastname@example.org|
|Daniel Bohsen||+45 3079 email@example.com|
|Melanie Raouzeos||+45 3075 firstname.lastname@example.org|
|Frank Daniel Mersebach (US)||+1 609 235 email@example.com|
Company announcement No 66 / 2014
Company announcement No 66 / 2014 http://hugin.info/2013/R/1866952/655927.pdf
Source:Novo Nordisk A/S